Evidence map›Paper›PMID 28928842›Full record

ArticleOncology letters2017

Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: A case report.

Yasuhiro Arakawa, Miho Tamura, Keisuke Aiba, Kazuhiko Morikawa, Daisuke Aizawa, Masahiro Ikegami, Masami Yuda, Katsunori Nishikawa

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yasuhiro ArakawaDepartment of Oncology and Hematology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Miho TamuraDepartment of Oncology and Hematology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Keisuke AibaDepartment of Oncology and Hematology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Kazuhiko MorikawaDepartment of Radiology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Daisuke AizawaDepartment of Pathology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Masahiro IkegamiDepartment of Pathology, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Masami YudaDepartment of Surgery, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Katsunori NishikawaDepartment of Surgery, Jikei University School of Medicine, Tokyo 105-8471, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is a relatively rare type of gastric cancer characterized by a high incidence of liver and lymph node metastases, and a poor prognosis. Few advanced AFPGC cases treated successfully with conventional chemotherapy have been reported thus far. Although the development of molecular-targeted therapy has improved the prognosis of various types of cancer, there are currently no tailored therapies for AFPGC. In the present report, the case of a chemotherapy-resistant recurrent AFPGC patient who exhibited a significant response to ramucirumab monotherapy is presented. Following six doses of ramucirumab, a metastatic lymph node displayed central necrosis, and the patient's serum AFP levels decreased from 12,800 to 225 ng/ml. AFPGC is known to have increased vascular endothelial growth factor (VEGF) expression and rich neovascularization. Furthermore, in the present case, tumor cells were positive for VEGF. Ramucirumab is a monoclonal antibody for VEGF receptor-2 and the first anti-angiogenic drug approved for the treatment of advanced gastric cancer. However, the clinical efficacy of ramucirumab in patients with AFPGC has not been reported previously. The present report suggests that AFP production in gastric cancer can be a predictor for the response to anti-angiogenic drugs such as ramucirumab.

Indexed as

alpha-fetoprotein-producing gastric canceranti-angiogenic therapychemotherapy-resistant gastric cancerramucirumab monotherapyrecurrent gastric cancer

Identifiers

PMID28928842
PMCPMC5588133
OpenAlexW2729345306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.